Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
News of the day
Zealand Pharma and Helsinn Healthcare Sign a Partnering Agreement for ZP1846, a novel GLP-2 agonistH
November 27, 2008- Zealand Pharma A/S and Helsinn Healthcare SA today announced that it has signed a partnering agreement, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to treat chemotherapy-induced diarrhea (CID), a debilitating condition affecting patients undergoing cancer treatment with a range of chemotherapies. moreEXONHIT LAUNCHES MOUSE GENOME SPLICEARRAYTM FOR USE IN HUMAN DISEASE MODELING STUDIES
Paris, France - November 27, 2008 - ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, announces today the availability of its new SpliceArrayTM for use in studying mouse models of human disease. These SpliceArrayTM products help our clients accelerate and refine their therapeutic target discovery and validation efforts. Using our high resolution expression profiling analysis, we identify novel transcripts coding for new protein variants that may be involved... moreHELSINN HEALTHCARE AND ZEALAND PHARMA SIGN A PARTNERING AGREEMENT FOR ZP1846, A NOVEL GLP-2 AGONIST
Lugano, November 27, 2008 - Helsinn Healthcare's Top management today announced that it has signed a partnering agreement with Zealand Pharma, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to treat chemotherapy-induced diarrhea (CID), a debilitating condition affecting patients undergoing cancer treatment with a range of chemotherapies. moreIndustry news search
Most Viewed News
- BioActives Obtains Patent for Highly Efficient Method of Producing Lutein Esters
- Pharmexa enters into an agreement regarding GV1001 with the Korean company KAEL Co. Ltd
- TopoTarget annonces positive phase II data BelCaP study in bladder cancer at AACR-EORTC-NCI 2008 Conference
- Cardiac Dimensions
- Quarterly Cashflow Report
- RSS Feed...
Latest news by category
Development
- EXONHIT LAUNCHES MOUSE GENOME SPLICEARRAYTM FOR USE IN HUMAN DISEASE MODELING STUDIES
- Wyeth and Progenics Announce Positive Outcome of Phase 3 Clinical Study of Subcutaneous RELISTOR for Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain
- NeuroSearch announces highly positive and supportive final results from a cardiovascular safety evaluation study with the anti-obesity drug tesofensine
- More news...
Intellectual Property
- BioActives Obtains Patent for Highly Efficient Method of Producing Lutein Esters
- Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
- Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
- More news...
Regulatory
- OPINION OF THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE PURSUANT TO ARTICLE 5(3) OF REGULATION (EC) No 726/2004, ON CONVENTIONAL ANTIPSYCHOTICS
- FDA Accepts Filing and Grants Priority Review for DX-88 for Hereditary Angioedema
- Caraco Pharmaceutical Laboratories, Ltd. Update on FDA Warning Letter
- More news...
Company releases
- Biologic drugs, particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai’s Humira, will drive the Psoriasis drug market to US$5 billion by 2017
- Market for cellular therapies will grow at a robust annual rate of more than 30 percent in the United States through 2017
- Advair’s patient share in newly diagnosed Asthma patients is declining
- More news...
Deals review
- HELSINN HEALTHCARE AND ZEALAND PHARMA SIGN A PARTNERING AGREEMENT FOR ZP1846, A NOVEL GLP-2 AGONIST
- 50 million dollar export deal for signed with Russia's largest pharmaceutical company
- Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
- More news...
PR Newswire
- CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East
- Sparta Systems Demonstrates Global Enterprise Quality Management Leadership at TrackWise(R) Connection User Conferences
- Remember, Remember...the End of December, Says Cat Charity
- More news...
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us